Angophar SA
1.7 FTEThe score of Angophar shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2024
Change 2021 → 2024: Equity +9 % Total assets +3 % Headcount (avg FTE) -6 %
Accounts of the company itself (not consolidated).
The full file covers 9 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Angophar's annual accounts
| 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|
| Net result | 136,623 € | ||||
| Equity | 681,310 € | ||||
| Cash | 218,806 € | ||||
| EBITDA | 167,920 € | ||||
| Total assets | €1.26m |
Filed annual accounts
- Year ended 31 Dec 2024filed on 29 Aug 2025
- Year ended 31 Dec 2023filed on 27 Aug 2024
- Year ended 31 Dec 2022filed on 31 Aug 2023
- Year ended 31 Dec 2021filed on 31 Aug 2022
- Year ended 31 Dec 2020filed on 19 Aug 2021
Angophar's financial analysis
- Solvency54.1%sector median: 37.8%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Angophar
Angophar's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0459.316.972
- VAT number
- BE0459316972
- Peppol
- Registered · 0208:0459316972 · as of 08 Nov 2026
- Legal form
- SA
- Incorporated
- 27 Nov 1996
- Registered office
- 1000 Brussels
- Size
- Micro · 1.7 FTE
- Latest accounts
- 2024 · filed on 29 Aug 2025
- Activity
- Retail sale of pharmaceutical products (NACE 47730)
Angophar (SA) has been based in Brussels since 1996, active in: retail sale of pharmaceutical products. For 2024, it reports a net profit of 136,623 € and equity of 681,310 €; its revenue is not published. With 1.7 full-time equivalents, it is a micro-enterprise by headcount. Its solvency stands at 54.1%, above the median of its sector (37.8%).
Companies similar to Angophar
Companies in the same business, of comparable size and area, outside its group.
- Oostveld - Pharma Retail sale of pharmaceutical products Lievegem · balance sheet €1.26m
- Pharmacie Chapelle-Willem Retail sale of pharmaceutical products Namur · balance sheet €1.26m
- Apotheek DELANG Retail sale of pharmaceutical products Puurs-Sint-Amands · balance sheet €1.26m
- Pharma Hesbaye Retail sale of pharmaceutical products Liège · balance sheet €1.27m
- Apoteek Van Elewyck - Sint Hubertus Retail sale of pharmaceutical products Hasselt · balance sheet €1.27m
- Groenenhoek Retail sale of pharmaceutical products Antwerp · balance sheet €1.25m
- Bornem Pharma Retail sale of pharmaceutical products Bornem · balance sheet €1.27m
- Bauphar Retail sale of pharmaceutical products Rebecq · balance sheet €1.24m
Frequently asked questions about Angophar
What is the revenue of Angophar?
Angophar files its accounts in a format where revenue is optional: it is not published for 2024.
What is the VAT number of Angophar?
In Belgium, the VAT number is the company number prefixed with BE: BE0459316972 for Angophar, if the company is VAT-registered. Its company number (CBE) is 0459.316.972.
Where is the registered office of Angophar?
According to the CBE register, the registered office of Angophar is in 1000 Brussels.
What is the equity of Angophar?
At the close of the 2024 financial year, the equity of Angophar amounts to 681,310 €, a solvency of 54.1% of total assets.
How many people work at Angophar?
1.7 full-time equivalents on average according to the 2024 social balance sheet.
Who manages Angophar?
The register lists 2 active mandates at Angophar. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Angophar
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →